Literature DB >> 1901084

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

D Y Leung1, C P Kelly, M Boguniewicz, C Pothoulakis, J T LaMont, A Flores.   

Abstract

We tested the hypothesis that children with chronic relapsing colitis induced by Clostridium difficile toxin have defective antibody responses to C. difficile toxins as a cause of their underlying illness. Six such children were tested for serum IgG and IgA antibody to C. difficile toxin A. These six children had lower IgG anti-toxin A levels than 24 healthy children (p = 0.026) and 18 healthy adults (p = 0.0008). Five patients treated with 400 mg intravenously administered gamma-globulin per kilogram every 3 weeks had significant increases in IgG (p = 0.01) but not IgA anti-toxin A (p = 0.406) levels, and all five had clinical resolution of their gastrointestinal symptoms as well as clearing of C. difficile cytotoxin B from their stools. These observations suggest that a deficiency of IgG anti-toxin A may predispose children to the development of chronic relapsing C. difficile-induced colitis. In such cases, intravenous gamma-globulin therapy may be effective in producing clinical remission.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901084     DOI: 10.1016/s0022-3476(05)83393-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  68 in total

Review 1.  Recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; C P Kelly
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 3.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 4.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

Review 5.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

6.  Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea.

Authors:  I L P Beales
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 8.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

9.  Intravenous immunoglobulin in treatment of Clostridium difficile colitis.

Authors:  Lokesh Shahani; Janak Koirala
Journal:  BMJ Case Rep       Date:  2012-05-08

10.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.